参考文献/References:
[1] 刘 宁,程 光. 恶性胶质瘤免疫治疗研究进展[J]. 中国
临床神经外科杂志,2013,18:251-253.
[2] 林婷婷,李 钢. 脑胶质瘤的综合临床治疗的研究进展
[J]. 中国临床神经外科杂志,2013,18:316-319.
[3] 颜 青,张华楸,王和平,等. 1 077例胶质瘤的临床和病
理学分析[J]. 中国临床神经外科杂志,2010,15:267-269.
[4] Sanai N, Chang S, Berger MS. Low-grade gliomas in adults
[J]. J Neurosurg, 2011, 115: 948.
[5] Parsons DW, Jones S, Zhang X, et al. An integrated genomic
analysis ofhuman glioblastoma multiforme [J]. Science,
2008, 321: 1807-1812.
[6] Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations
in gliomas [J]. N Engl J Med, 2009, 360: 765-773.
[7] Johnson BE, Mazor T, Hong C, et al. Mutational analysis
reveals the origin and therapy-driven evolution of recurrent
glioma [J]. Science, 2014, 343(6167): 189-193.
[8] Filatova A, Acker T, Garvalov BK. The cancer stem cell
niche(s): the crosstalk between glioma stem cells and their
microenvironment [J]. Biochim Biophys Acta, 2013, 1830:
2496-508.
[9] 汪 宇,丁建军. 脑胶质瘤干细胞Hedgehog信号通路研
究进展[J]. 中国临床神经外科杂志,2014,19:763-765.
[10] 宫崧峰,丁建军,汪 宇,等. 抑制Hedgehog信号通路对
人脑胶质瘤肿瘤干细胞体外增殖的影响[J]. 中国临床神
经外科杂志,2015,20:96-98.
[11] Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer
genome landscapes [J]. Science, 2013, 339: 1546-1558.